(Q84574792)
Statements
Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML (English)
Z Y Lim
W Ingram
R Brand
A Ho
M Kenyon
J Marsh
21 September 2009